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Over 90% of the adult human population is chronically infected with the Epstein-Barr virus (EBV), an oncogenic herpesvirus.
EBV primarily infects naive human B cells and persists latently in memory B cells. Most individuals experience an asymptomatic
infection that is effectively controlled by the adaptive immune response. However, EBV-associated lymphomas can develop in
immunocompromised individuals. These tumors typically express all nine EBV latent proteins (latency III). Latency III is also
associated with the expression of three precursor microRNAs (miRNAs) located within the EBV BHRF1 gene locus. The role of
these BHRF1 miRNAs was unclear until recent in vitro studies demonstrated that they cooperate to enhance virus-induced B cell
transformation and decrease the antigenic load of virus-infected cells, indicating that the BHRF1 miRNA cluster may serve as a
novel therapeutic target for the treatment of latency III EBV-associated malignancies. However, to date, it is not known if
BHRF1 miRNAs enhance virus-induced oncogenesis and/or immune evasion of EBV in vivo. To understand the in vivo contri-
bution of the BHRF1 miRNA cluster to EBV infection and EBV-associated tumorigenesis, we monitored EBV infection and as-
sessed tumor formation in humanized mice exposed to wild-type virus and a viral mutant (123) that lacks all three BHRF1
miRNAs. Our results demonstrate that while the BHRF1 miRNAs facilitate the development of acute systemic EBV infection,
they do not enhance the overall oncogenic potential of EBV in vivo.
Epstein-Barr Virus (EBV), a human gamma herpesvirus, iswidespread in all populations; more than 90% of adults world-
wide have antibodies to EBV, and infection with EBV persists for
the life of its host (1). In healthy individuals, EBV is effectively
controlled by the immune system and typically remains asymp-
tomatic. Upon primary infection, virus-targeted B cells undergo a
period of rapid proliferation until either CD8 T cells mount an
efficient antiviral response (2) or infected B cells differentiate into
a pool of latently infected memory-like B cells (3). When the im-
mune system is suppressed, EBV can induce the development of
certain lymphomas (4–6).
EBV-associated malignancies that arise in immunodeficient
individuals (i.e., posttransplant and AIDS patients) typically ex-
press all nine EBV latent proteins (latency III): six Epstein-Barr
virus nuclear antigens (EBNA) and three latent membrane pro-
teins (LMP) (1, 3). Although most EBV-associated malignancies
respond poorly to chemotherapy, immunotherapy approaches
that boost or supplement the patient’s EBV-specific T cell re-
sponse have been successful in treating some latency III tumors
due to their high antigenic load (4). However, these strategies,
which typically involve the adoptive transfer of autologous or al-
logeneic EBV-specific T cells stimulated in vitro, are often labori-
ous and technically challenging (4). Therefore, new therapeutic
targets and approaches are urgently needed for the treatment of
EBV-associated malignancies.
In addition to the nine virus-encoded latent proteins, during
latency III, EBV-transformed B cells also express a cluster of three
precursor microRNAs (miRNAs) located within the EBV BHRF1
gene locus (1, 7). miRNAs are a class of RNAs 21 to 23 nucleotides
(nt) long that posttranscriptionally regulate gene expression by
binding to target sites on complementary mRNAs (8). Two of the
three BHRF1 miRNAs are located in the BHRF1 3= untranslated
region and one is located immediately 5= to the BHRF1 lytic
mRNA transcription start site (7, 9). The roles of these BHRF1
miRNAs were unclear until recent in vitro studies using viral
knockouts in lymphoblastoid cell lines (LCLs), a widely used cel-
lular model of latency III EBV infection, revealed that the BHRF1
miRNAs cooperate to enhance B cell expansion, reduce levels of
latent gene expression, and possibly also inhibit apoptosis (10–
12). Additionally, as circumstantial evidence for the roles of these
miRNAs, studies that comprehensively examined the targets of
EBV miRNAs have shown that BHRF1 miRNAs bind a number of
targets involved in proliferation, latent gene expression, and reg-
ulation of apoptosis (13, 14).
Collectively, these in vitro studies demonstrate that BHRF1
miRNAs cooperate to expand the viral reservoir and decrease the
antigenic load and suggest that the BHRF1 miRNA cluster could
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serve as a novel therapeutic target for the treatment of latency III
EBV-associated malignancies. However, to date, it is not known if
BHRF1 miRNAs enhance the oncogenic potential and/or enhance
immune evasion of EBV in vivo. Here, we utilized a humanized
mouse model of EBV infection and tumorigenesis to examine the
in vivo role of BHRF1 miRNAs. Until recently, in vivo studies with
EBV have been limited; EBV exhibits very restricted species tro-
pism (humans and New World primates such as the common
marmoset and cottontop tamarin) (15, 16). Humanized mice gen-
erated by transplanting CD34 hematopoietic stems cells into im-
mune-deficient mice devoid of mouse lymphoid cells are system-
ically reconstituted with human myeloid and lymphoid cells,
including human B cells (the primary target cell of EBV) (17). EBV
infection of humanized mice recapitulates several key aspects of
human infection, including a virus-specific CD8 T cell immune
response and the development of latency III EBV-associated tu-
mors (18–20). To understand the in vivo contribution of the
BHRF1 miRNA cluster to EBV infection and EBV-induced tu-
morigenesis, we monitored EBV infection and assessed tumor for-
mation in humanized mice exposed to wild-type (WT) virus, a
viral mutant (123) that lacks all three BHRF1 miRNAs, and a
revertant (REV) virus that was created by reexchanging the orig-
inal BHRF1 miRNA sequences back into the 123 mutant (11).
Our results demonstrate that while the BHRF1 miRNAs facilitate
the development of acute systemic EBV infection, they do not
enhance the overall oncogenic potential of EBV in vivo.
MATERIALS AND METHODS
EBV production and titer quantification. Viral particles were produced
from HEK293 cells harboring a hygromycin-resistant, green fluorescent
protein (GFP)-expressing, B95.8 EBV bacmid as described previously
(21). Briefly, bacmid-containing cells were transfected with BZLF1- and
gp110-expressing plasmids using Fugene (Roche, Indianapolis, IN) and
the manufacturer’s protocol (21, 22). Two days postinfection, cell super-
natants containing viral particles were passed through 0.45-m-pore-size
filters and concentrated in Amicon Ultra-15 centrifugal filter units (Mil-
lipore, Billerica, MA). Virus titers were determined using green Raji units
(GRU) (23). For each set of mouse exposures, we utilized virus stocks
(WT, REV, and 123) that were prepared on the same day. Titers of virus
stocks were determined in the same Raji cells on the same day. Frozen
aliquots of virus were used for titration so as to mimic those utilized for
exposures.
Preparation of humanized mice. Hematopoietic CD34 stem cells
were isolated from enzymatically digested human fetal liver tissue by
positive immunomagnetic isolation as previously described (24). Hu-
manized mice were prepared by transplanting human fetal liver-de-
rived hematopoietic CD34 stem cells (2  105 to 3.5  105 cells per
mouse) intrahepatically into sublethally irradiated (100 cGy) 1-day-
old NOD.Cg-Prkdcscid IL2rtm1Wjl/SzJ (NSG; The Jackson Laboratory,
Bar Harbor, ME) mice. Reconstitution with human hematopoietic
cells was monitored in peripheral blood by flow cytometry every 3 to 4
weeks as previously described (24). Mice were maintained under spe-
cific-pathogen-free conditions by the Division of Laboratory Animal
Medicine at the University of North Carolina (UNC) at Chapel Hill.
EBV exposure of humanized mice. Humanized mice were challenged
with 3.6  105 GRU of WT, REV or 123 EBV by injecting virus directly
into the spleen (up to a 225-l total volume) as previously described (24,
25). Briefly, mice were anesthetized and prepared for surgery, and a small
incision was made on the left side of the abdomen to expose the spleen. If
necessary, viral stocks were diluted with plain RPMI tissue culture me-
dium immediately prior to exposure to ensure that an equivalent inocu-
lum dose and volume were injected into each mouse. Following exposure,
the incision site was sutured closed, and mice were allowed to fully recover
from surgery. Two sets of splenic exposures were performed and with
different preparations of virus.
Analysis of EBV infection in humanized mice. EBV infection in hu-
manized mice was monitored in peripheral blood by measuring the levels
of viral DNA in plasma and cells with a real-time PCR assay using the
forward and reverse primers 5=-GGAACCTGGTCATCCTTGC-3= and
5=-ACGTGCATGGACCGGTTAAT-3=, respectively, and the probe 5=-FA
M-CGCAGGCACTCGTACTGCTCGCT-Q-3= (where FAM is 6-
carboxyfluorescein and Q is 6-carboxytetramethylrhodamine); the assay
limit of detection was 375 DNA copies/ml (cell-associated EBV DNA) or
560 DNA copies/ml (cell-free EBV DNA) (26). The expansion, memory
phenotype, and activation status of human CD8 T cells were monitored
in peripheral blood pre- and postexposure by flow cytometry.
Mice were euthanized at 18 weeks postexposure or earlier if they ex-
perienced greater than 20% weight loss and/or appeared moribund, and a
necropsy was performed to assess the presence of tumors. Tumors were
harvested, snap-frozen, and stored at 80°C for subsequent nucleic acid
extraction and real-time PCR analysis. Tumor images were taken with an
iSight color camera, and the white balance and brightness were adjusted in
Adobe Photoshop CS5.
RNA isolation from mouse tumors and real-time PCR of EBV latent
genes and BHRF1 miRNAs. RNA was isolated from mouse tumors using
TRIzol reagent according to the manufacturer’s protocol (Life Technolo-
gies, Grand Island, NY). The quality and quantity of the RNA were mea-
sured using a Nanodrop 2000 (Thermo Scientific, Wilmington, DE), and
the RNA was used for reverse transcription. For cDNA from mRNA, 500
ng of total RNA was used for reverse transcription using random primers
and a High Capacity cDNA Reverse Transcription kit (Applied Biosys-
tems, Carlsbad, CA). EBNA2 and LMP1 were detected via quantitative
PCR (qPCR) using SYBR chemistry, a StepOnePlus machine (Applied
Biosystems, Carlsbad, CA) and the following primers: EBNA2, 5=-GC
TTAGCCAGTAACCCAGCACT-3= (forward) and 5=-TGCTTAGAAGG
TTGTTGGCATG-3= (reverse); LMP1, 5=-AATTTGCACGGACAGGCAT
T-3=; (forward) and 5=-AAGGCCAAAAGCTGCCAGAT-3= (reverse).
Relative levels of EBNA2 and LMP1 were quantified using beta-actin
mRNA as an internal reference. For cDNA from miRNA, 10 ng of total
RNA was used for reverse transcription using miRNA-specific primers
(Applied Biosystems, Carlsbad, CA) and a TaqMan MicroRNA Reverse
Transcription kit (Applied Biosystems, Carlsbad, CA). BHRF1 miRNAs
were detected via qPCR using TaqMan chemistry, a StepOnePlus ma-
chine, and miRNA-specific primers (Applied Biosystems, Carlsbad, CA)
(27, 28). RNU48 snoRNA was used as an internal reference to calculate the
relative levels of BHRF1 miRNA expression.
Statistical analyses. Statistical analyses were performed in Prism, ver-
sion 5 (Graph Pad, La Jolla, CA). We used a log rank Mantel-Cox test to
compare the rates of viral DNA detection in the peripheral blood and
survival between WT/REV and 123 EBV-exposed mice. A two-tailed
Mann-Whitney U test was used to compare the peak cell-associated and
cell-free viral loads and the mean percentages of human cell populations
in the peripheral blood of WT, REV, and 123 EBV-exposed mice. We
compared tumor incidence between WT/REV and 123 EBV-exposed
mice with Fisher’s exact test.
RESULTS
Reconstitution of humanized mice with human hematopoietic
cells. Humanized mice were created by injecting human fetal liv-
er-derived CD34 hematopoietic stem cells into the liver of sub-
lethally irradiated 1-day-old NSG mice. The humanized mice gen-
erated for this study represented four different human donors.
Systemic reconstitution of humanized mice with human hemato-
poietic cells (CD45) was confirmed in peripheral blood prior to
exposure by flow cytometry (mean percentage of human CD45
cells  standard deviation [SD] for WT virus-exposed mice,
43.8%  15.2%; for REV virus-exposed mice, 48%  6.2%; for
123 virus-exposed mice, 40.1%  15.2%) (Fig. 1A). In addition,
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we also verified systemic reconstitution of mice with human B
cells (CD19) (mean percentage of human CD19  SD for WT
virus-exposed mice, 42.9%  17.1%; for REV virus-exposed mice,
32.7%  10.7%; for 123 virus-exposed mice, 36.5%  18.2%)
and human T cells (CD3) (mean percentage of human CD3
SD for WT virus-exposed mice, 37.7%  16.6%; for REV virus-
exposed mice, 54.7%  8.1%; for 123 virus-exposed mice,
43.7%  20.6%) (Fig. 1B and C). We observed no significant
difference in the percentages of human hematopoietic cells, B
cells, or T cells in peripheral blood of mice exposed to WT, REV,
or 123 virus (Fig. 1).
Systemic EBV infection in WT/REV and 123 virus-exposed
mice. Once we established systemic reconstitution of mice with
human hematopoietic cells, we exposed humanized mice to WT,
REV, or 123 EBV by injecting virus directly into the spleen. We
then monitored systemic EBV infection by measuring peripheral
blood viral load levels with real-time PCR. As expected from the
nature of and in vitro characterization of the REV virus, we de-
tected no significant in vivo differences in EBV infection between
mice exposed to the WT and REV viruses (data not shown).
Therefore, for the remainder of this report, we analyze the results
generated from WT and REV EBV-exposed mice together and
compare them to those of 123 virus-exposed mice.
We observed a significant delay in the appearance of viral DNA
(cell-associated and/or cell-free) in the peripheral blood of mice
exposed to 123 virus in comparison to mice exposed to WT/REV
EBV (Fig. 2). Viral DNA was readily detected in the peripheral
blood of 5/10 (50%) WT/REV virus-exposed mice as early as 2
weeks postexposure. When we performed a PCR analysis of tissues
harvested from a WT virus-exposed mouse negative for viral DNA
in the peripheral blood at 2 weeks postexposure, we detected viral
DNA in both the spleen and liver, indicating that these tissues are
early sites of virus replication prior to the appearance of viremia
(data not shown). We detected viral DNA in the peripheral blood
of all remaining mice exposed to WT/REV virus by 4 weeks post-
exposure (Fig. 2). In contrast, we detected viral DNA in the pe-
ripheral blood of only 1/11 (9%) 123 virus-exposed mice at 2
weeks postexposure and in only 6/11 (54%) 123 EBV-exposed
mice by 4 weeks postexposure (Fig. 2). We detected viral DNA in
the peripheral blood of all mice exposed to 123 virus by 6 weeks
postexposure (Fig. 2).
Following the initial appearance of viral DNA in peripheral
blood of EBV-exposed mice, we were able to periodically detect
cell-associated (Fig. 3A and C) and cell-free (Fig. 3B and D) viral
DNA in peripheral blood cells and plasma, respectively, of WT/
REV and 123 virus-infected mice throughout the experiment. In
addition, although we observed a delay in the appearance of viral
DNA in the peripheral blood of 123 virus-infected mice, we did
not observe a significant difference in the peak cell-associated (Fig.
3E) or cell-free (Fig. 3F) viral loads between WT/REV and 123
virus-exposed mice with detectable viremia.
Collectively, these results reveal that systemic EBV infection is
delayed in mice exposed to virus lacking the BHRF1 miRNA clus-
ter, as determined by the appearance of viral DNA in peripheral
blood following exposure. However, once systemic infection was
established, we observed no significant difference in the peak cell-
associated or cell-free peripheral blood viral loads of mice exposed
to virus that does or does not possess the three BHRF1 miRNAs.
FIG 1 Reconstitution of humanized mice with human hematopoietic cells. Reconstitution of humanized mice with human hematopoietic cells was monitored
in the peripheral blood by flow cytometry. The mean percentages of human hematopoietic cells (CD45), B cells (CD19), and T cells (CD3) in the peripheral
blood of humanized mice prior to exposure to WT, REV or 123 EBV are shown. There was no significant difference in the percentages of human cells in the
peripheral blood of mice exposed to WT, REV, or 123 EBV (two-tailed Mann-Whitney U test, significance defined as P  0.05).
FIG 2 Detection of viral DNA in the peripheral blood of humanized mice
exposed to EBV. Spleens of humanized mice were injected with 3.6  105 GRU
of WT (n  7), REV (n  3), or 123 (n  11) EBV. Following splenic
exposure, infection was monitored in peripheral blood with real-time PCR. A
Kaplan-Meier plot illustrates the week postexposure when EBV DNA was first
detected in the peripheral blood of mice exposed to WT/REV or 123 EBV.
The rate of viral DNA detection in the peripheral blood of mice exposed to
WT/REV or 123 EBV was compared with a log rank Mantel-Cox test (P 
0.0083).
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The effect of BHRF1 miRNAs on the peripheral blood CD8
T cell response during acute EBV infection. In vivo, acute EBV
infection elicits a potent cell-mediated immune response that is
characterized by peripheral blood CD8 T cell expansion, activa-
tion, and acquisition of a memory phenotype. While the CD8 T
cell response primarily targets lytic viral proteins, particular latent
proteins (EBNA1, EBNA3A, and EBNA3C) are also targeted by
CD8 T cells during EBV infection. However, the magnitude of
the CD8 T cell response to latent antigens during acute infection
is less robust than the response to lytic antigens and peaks during
convalescence (29). In vitro, BHRF1 miRNAs have been shown to
reduce expression of latent viral proteins in infected B cells, which
may facilitate immune evasion of latently infected B cells in vivo
(30). B cells infected with the 123 mutant in vitro not only exhibit
FIG 3 Detection of cell-associated and cell-free EBV DNA in the peripheral blood of EBV-exposed humanized mice. The presence of EBV DNA in peripheral
blood cells (cell-associated DNA) and plasma (cell-free DNA) of WT/REV (n  10) and 123 (n  11) virus-exposed mice was determined with real-time PCR.
The corresponding cell-associated (A and C) and cell-free (B and D) peripheral blood viral loads for each mouse are indicated with the same symbol. A dashed
line indicates the assay limit of detection (cell-associated EBV DNA, 375 DNA copies/ml; cell-free EBV DNA, 560 DNA copies/ml). Cell-associated EBV DNA was
detected in the peripheral blood of 9/10 WT/REV EBV-exposed mice and 11/11 123 EBV-exposed mice. Cell-free EBV DNA was detected in the peripheral
blood of 9/10 WT/REV EBV-exposed mice and 9/11 123 EBV-exposed mice. There was no significant difference in the peak cell-associated (E) or cell-free (F)
EBV viral loads in the peripheral blood of WT/REV and 123 EBV-exposed mice with detectable viremia (two-tailed Mann-Whitney U test; cell-associated, P 
0.4964; cell-free, P  0.6517).
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slower cell growth kinetics but also display increased expression of
latent viral proteins compared to their WT/REV virus-infected
counterparts (30). Therefore, we next wanted to examine the
CD8 T cell response to EBV infection in the peripheral blood of
mice exposed to the WT/REV and 123 viruses. We utilized flow
cytometry to monitor the expansion, activation, and memory
phenotype of CD8 T cells in the peripheral blood of mice pre-
and postexposure to WT/REV and 123 EBV.
Although we observed an increase in the percentage of CD8 T
cells in the peripheral blood of both WT/REV and 123 EBV-
exposed mice during the course of infection, peripheral blood
CD8 T cell expansion was significantly more robust in WT/REV
virus-infected mice at 4 and 6 weeks postexposure than in mice
infected with the 123 viral mutant (Fig. 4A). In addition, while
CD8 T cell expansion in the peripheral blood peaked at week 6
postexposure during WT/REV virus infection, CD8 T cell ex-
pansion was delayed in 123 virus-infected mice and did not peak
until 8 weeks postexposure (Fig. 4A). We also observed an increase
in the percentage of activated CD8 T cells (CD38 HLA-DR) in
the peripheral blood of mice following exposure to the WT/REV
and 123 viruses (Fig. 4B). However, peripheral blood CD8 T
cell activation was more pronounced in WT/REV virus-infected
mice at early time points postexposure than in 123 virus-infected
mice, reaching significance at 6 weeks postexposure (Fig. 4B). Al-
though we observed a delay in peripheral blood CD8 T cell ex-
pansion and activation in mice infected with the 123 mutant,
we did not observe a significant difference in the percentage of
peripheral blood CD8 T cells exhibiting a memory phenotype
(CD45RA) in mice infected with the WT/REV and 123 viruses
(Fig. 4C). We observed an increase in the percentage of memory
CD8 T cells in the peripheral blood of both WT/REV and 123
virus-infected mice (Fig. 4C). Memory (mean  SD, 28.8% 
29.67%; n  4) and activated (4.15%  3.46%; n  2) CD8 T
cells were also detected in the peripheral blood of uninfected hu-
manized mice, albeit at much lower levels than those observed in
EBV-infected mice.
All together, these results indicate that mice infected with the
WT/REV and 123 viruses exhibit peripheral blood CD8 T cell
expansion, activation, and acquisition of a memory phenotype,
mimicking the human condition. However, mice infected with
virus lacking the BHRF1 miRNA cluster displayed reduced levels
of peripheral blood CD8 T cell expansion and activation in com-
parison to their WT/REV virus-infected counterparts at early time
points postexposure.
The in vivo contribution of BHRF1 miRNAs to EBV-induced
tumorigenesis. In most individuals, EBV is effectively controlled
by the immune system and establishes an asymptomatic chronic
infection (1). However, EBV can induce the development of cer-
tain types of B cell lymphomas when the immune system is sup-
pressed (5, 6). Although in vitro studies indicate that the BHRF1
miRNAs facilitate EBV-mediated B cell transformation (11), the
extent to which these BHRF1 miRNAs contribute to EBV-induced
tumorigenesis in vivo has not been investigated.
In order to assess the contribution of the BHRF1 miRNA clus-
ter to EBV-induced tumor formation in vivo, we examined hu-
manized mice infected with WT/REV and 123 EBV for the pres-
ence of tumors at 18 weeks postexposure or sooner if they
experienced greater than 20% weight loss and/or appeared mori-
bund. Although mice infected with the 123 viral mutant experi-
enced a delay in the establishment of systemic EBV infection and
in peripheral blood CD8 T cell expansion and activation, we
observed no significant difference in the survival rates between
mice infected with WT/REV and 123 EBV (Fig. 5). At necropsy,
tumors were readily detected in multiple organs of both WT/REV
and 123 EBV-infected mice and were most frequently observed
in the spleen, liver, and kidney (Fig. 6 and Table 1). We also ob-
served no significant difference in tumor incidence or tumor lo-
cation between WT/REV and 123 EBV-infected mice (Fig. 6 and
Table 1).
In vivo, EBV-associated tumors can be classified by the expres-
sion patterns of the nine EBV latent genes (i.e., latency status).
BHRF1 miRNAs are expressed only in tumors that display latency
III, which is characterized by the expression of all nine EBV latent
genes (1, 7). Although other laboratories have reported that EBV-
infected humanized mice generated via transplantation of hu-
man CD34 hematopoietic stem cells into NOG (NOD/Shi-
scid/IL2Rnull) and NSG mice primarily develop tumors with
latency III (18, 19), it is possible that our data are the result of the
development of latency I and/or II tumors in WT/REV and/or
123 EBV-infected mice. Therefore, we determined the latency
FIG 4 Expansion, activation, and memory phenotype of CD8 T cells in peripheral blood following EBV exposure. Flow cytometry was utilized to monitor the
expansion, activation status, and memory phenotype of CD8 T cells in the peripheral blood of mice pre- and postexposure to WT/REV or 123 EBV. (A) The
mean ( standard error of the mean) percentage of CD3 T cells that express CD8. (B) The mean ( standard error of the mean) percentage of activated (CD38
HLA-DR) CD8 T cells. (C) The mean ( standard error of the mean) percentage of memory (CD45RA) CD8 T cells. A two-tailed Mann-Whitney U test
was used to compare the percentages of human CD8 T cells, activated CD8 T cells, and memory CD8 T cells in the peripheral blood of WT/REV and 123
EBV-exposed mice (*, P  0.05; **, P 	 0.01).
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status of tumors harvested from WT, REV, and 123 EBV-in-
fected mice by determining their patterns of expression of the EBV
latent genes LMP1 and EBNA2 with real-time PCR (latency I,
LMP1 EBNA2; latency II, LMP1 EBNA2; latency III,
LMP1 EBNA2) (6). All tumors analyzed from WT, REV and
123 EBV-infected mice expressed LMP1 and EBNA2 latency
genes (latency III) (Fig. 7A). In addition, we also confirmed ex-
pression of BHRF1 miRNAs in the majority of tumors harvested
from WT and REV virus-infected mice (Fig. 7B). Collectively, our
results confirm that, in this humanized mouse system, EBV in-
duces the formation of latency III tumors in multiple organs and
demonstrate that BHRF1 miRNAs are expressed in vivo within
these tumors. In addition, our data demonstrating no significant
difference in the incidence, location, or latency status of tumors har-
vested from WT/REV and 123 EBV-infected mice indicate that
the BHRF1 miRNA cluster does not enhance EBV-induced tu-
morigenesis in vivo.
DISCUSSION
In immune-compromising situations, EBV-induced B cell growth
can cause lymphoproliferative disorders such as AIDS-associated
lymphomas (e.g., diffuse large B cell lymphoma [DLBCL]) (31)
and posttransplant lymphoproliferative disease (PTLD) (1). EBV
in typical DLBCL and PTLD cells expresses all nine latent proteins
(latency III) (1, 3). Studies in LCLs have shown that these latent
proteins are necessary for EBV-induced B cell transformation
(32–36). Recently, in vitro experiments have also indicated that
during latency III, the B-cell-transforming properties of EBV are
strongly potentiated by the virus-encoded BHRF1 miRNAs (11).
In this study, we utilized a humanized mouse model of EBV infec-
tion and tumorigenesis to examine the contribution of BHRF1
miRNAs to the oncogenic potential of EBV in vivo in order to
determine if these miRNAs may serve as an additional viral target
for the therapeutic treatment of latency III EBV-associated malig-
nancies.
Our in vivo results indicate that BHRF1 miRNAs accelerate the
development of systemic EBV infection. Viremia was significantly
delayed in humanized mice infected with the 123 mutant virus
lacking the three BHRF1 miRNAs. The delay in viremia that we
observed in 123 EBV-infected mice may be due to a lower
growth rate of infected B cells. Previous in vitro experiments dem-
onstrated that primary B cells infected with wild-type virus ex-
panded more quickly than cells infected with 123 EBV. At 4
weeks postinfection, wild-type virus-infected B cells expanded
from 2  106 cells to 3.6  108 cells while 123 EBV-infected cells
expanded to only 1.3  108 cells (
3-fold fewer cells) (11). Al-
though we observed a delay in the appearance of viral DNA in the
peripheral blood of 123 EBV-infected mice, once viremia was
established, we observed no significant difference in the peak viral
loads between WT/REV and 123 EBV-infected mice. These re-
sults indicate that while BHRF1 miRNAs may accelerate expan-
sion of infected B cells, B cells infected with virus lacking BHRF1
miRNAs are ultimately able to expand to similar levels as their
wild-type virus-infected counterparts in vivo. Although we did not
directly measure the amount of lytic viral replication in EBV-
infected mice, our data demonstrating no significant difference
between the peak cell-free and cell-associated viral loads of WT/
FIG 5 Survival rate of EBV-infected humanized mice. A Kaplan-Meier plot
depicts the survival rate of mice exposed to either WT/REV or 123 EBV. The
rates of survival between WT/REV and 123 EBV-exposed mice were com-
pared with a log rank Mantel-Cox test (P  0.9171).
FIG 6 Tumor incidence in humanized mice exposed to WT/REV or 123
EBV. The presence and location of tumors in mice infected with WT/REV (n 
9) or 123 (n  11) EBV were assessed at necropsy. (A) The number of
WT/REV and 123 EBV-exposed mice with visible tumors at necropsy in the
spleen, liver, kidney, and other organs. No significant (ns) difference in tumor
incidence or tumor location was observed between WT/REV and 123 EBV-
exposed mice at harvest (Fisher’s exact test, significance defined as P  0.05).
(B) Images of the spleen, liver, and kidney of WT/REV and 123 EBV-exposed
mice. Tumors are indicated with arrows.
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REV and 123 EBV-infected mice also suggest that the delay in
viremia observed following 123 EBV exposure is not due to de-
creased lytic viral replication.
Robust killing of EBV-infected cells by virus-specific CD8 T
cells could also account for a delay in the appearance of viremia
during 123 EBV infection. Previously published in vitro studies
revealed that B cells infected with 123 virus expressed higher
levels of the viral proteins expressed during latency III, including
those most commonly targeted by CD8 T cells (EBNA1,
EBNA3A, and EBNA3C) (11, 29). It is therefore possible that in-
creased antigen presentation makes 123 virus-infected cells
more susceptible to CD8 T cell killing in vivo and that the delay in
the appearance of viral DNA in peripheral blood that we observed
during 123 virus infection is due to increased killing of infected
cells. Contradicting this rationale was the observation of signifi-
cantly less CD8 T cell proliferation and activation in the periph-
eral blood of 123 virus-infected mice than in mice infected with
WT/REV virus at early time points postexposure (week 4 and/or 6
postexposure). In this study, limited sample volume (
150 l of
blood per mouse) precluded a longitudinal analysis of the EBV-
specific T cell response (i.e., tetramer staining, cytotoxicity assays,
etc) following exposure. However, our in vivo data combined with
previously published in vitro studies demonstrating decreased
growth of 123 virus-infected cells suggest that decreased growth
and not increased killing of infected cells decreases the reservoir of
virus-infected cells, thereby delaying the detection of viremia in
mice infected with virus lacking the BHRF1 miRNAs. In addition,
these data indicate that the decreased peripheral blood CD8 T
cell proliferation and activation that we observed following 123
virus infection is most likely due to a lower level of EBV-infected
cells present systemically at early time points postexposure.
Although viral mutants lacking the EBV latent protein EBNA1,
EBNA2, EBNA-LP, or LMP-1 exhibit a drastic reduction in their
ability to transform B cells (32–36), it is not known if these pro-
teins are sufficient for B cell transformation in vivo or if other
virus-encoded components contribute to the transforming poten-
tial of EBV. One of our goals here was to determine if the virus-
encoded BHRF1 miRNAs significantly promote EBV-induced on-
cogenesis in vivo given their documented ability to enhance B cell
transformation in vitro (11). Therefore, we exposed humanized
mice to WT/REV EBV or virus lacking the three BHRF1 miRNAs
(123 EBV) and subsequently monitored survival and tumor for-
mation. Although 123 EBV exhibits a reduced capacity to trans-
form B cells in vitro, we did not observe a significant difference in
survival or tumor formation between mice exposed to WT/REV
and 123 EBV. At necropsy, we consistently observed tumors in
EBV-infected mice (88% of WT/REV and 73% of 123 virus-
infected mice). Several WT/REV and 123 EBV-infected mice
possessed tumors in multiple organs, most commonly the liver,
spleen, and kidney, which is consistent with what other investiga-
tors have reported in this humanized EBV mouse model (18, 19).
We also confirmed LMP1 and EBNA2 expression in all tumors





humanization at exposure by
cell type (%)a
Peak viral load





copies/ml Day Day Spleen Liver Kidney Other
WT 1b C 61 12 60 NDd 14 ND 14 14c    
2 D 54 52 34 68,347 60 79,197 60 60    
3 D 49 40 39 38,892 28 30,174 28 124    
4 A 44 40 40 81,495 17 857,847 17 31    
5 A 48 47 40 768,867 27 3,087,704 17 27    
6 A 37 40 46 141,315 66 302,618 17 66    
7 B 14 69 5 928,928 36 1,161,146 27 36    
REV 8 D 50 42 49 39,011 28 41,642 28 57    
9 C 41 21 64 138,293 28 352,638 28 47    
10 D 53 35 51 56,797 28 120,803 28 124    
123 11 C 47 32 49 26,780 54 113,798 54 54    
12 C 50 23 53 182,496 83 3,688,297 96 106    
13 C 34 17 65 ND 77 21,988 42 77    
14 D 43 47 39 6,865 83 100,732 55 95    
15 D 64 55 30 ND 34 2,288 34 34    
16 D 34 37 52 8,083 42 16,766 42 118    
17 A 60 18 68 21,759 28 154,749 28 51    
18 B 15 60 1 234,490 55 765,365 42 55    
19 B 28 64 19 4,494,995 65 13,414,096 65 65    
20 A 44 38 42 52,774 42 17,540 42 51    
21 A 22 11 63 380,633 65 513,500 65 65    
a Gating strategy: live ¡ hCD45 ¡ hCD19 or hCD3 (where h is human).
b Not included in tumor analyses.
c EBV DNA detected in spleen and liver at harvest.
d ND, not detected.
e Presence () or absence () of tumor(s) is indicated.
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analyzed from WT/REV and 123 EBV-infected mice, character-
istic of latency III EBV infection. In addition, we detected expres-
sion of one or more of the three BHRF1 miRNAs in the majority of
tumors isolated from WT/REV EBV-infected mice (70%) and
confirmed the absence of BHRF1 miRNAs in tumors harvested
from 123 virus-infected mice. Collectively, these results indicate
that latency III EBV-associated malignancies can develop in vivo
in the presence or absence of BHRF1 miRNAs.
Although we detected expression of both LMP1 and EBNA2 in
all tumors analyzed from EBV-infected mice, which is character-
istic of latency III, we did not detect BHRF1 miRNA expression in
all tumors analyzed from WT/REV EBV-infected mice (30%). It is
possible that our inability to detect BHRF1 miRNA expression
could be due to a mixture of latency I/II and III EBV-infected B
cells within these tumors. BHRF1 miRNAs are not expressed dur-
ing latency I or II (7), and the presence of latency I/II EBV-infected
B cells within these tumors could potentially decrease the overall
level of BHRF1 miRNA expression. While we cannot rule out that
latency I or II EBV-infected B cells are not present within these
tumors, or within tumors harvested from 123 virus-infected
mice, we detected expression of both LMP1 and EBNA2 in all
tumors analyzed, albeit at various levels. We also observed expres-
sion of both LMP1 and EBNA2 in LCLs, our positive control for
latency III EBV infection and BHRF1 miRNA expression (Fig. 7).
In addition, other laboratories have also reported that EBV infec-
tion induces the formation of latency III malignancies in this hu-
manized mouse model (18, 19). Alternatively, our inability to de-
tect BHRF1 miRNA expression in all tumors analyzed from WT/
REV virus-infected mice may also indicate that, in vivo, the levels
of BHRF1 miRNA expression vary among latency III tumors. In
some instances, BHRF1 miRNA may be expressed at levels below
our current limit of detection. Previous studies investigating
FIG 7 Expression of EBV latent proteins and BHRF1 miRNAs in tumors harvested from EBV-infected mice. We analyzed tumors harvested from four WT/REV
and four 123 EBV-infected mice to assess latency status (A) and BHRF1 miRNA expression (B). The corresponding mouse number and location (S, spleen; L,
liver; K, kidney) of each tumor are indicated. Latency status was determined by the relative expression level of EBV latent proteins LMP1 and EBNA2 and was
defined as follows: latency I, LMP1 EBNA2; latency II, LMP1 EBNA2; and latency III, LMP1 EBNA2. The relative expression level of each BHRF1
miRNA is also indicated (the typically less abundant of the two possible BHRF1-2 miRNAs is noted with an asterisk). LCLs were used as a positive control for
latency III and BHRF1 miRNA expression.
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BHRF1 miRNA expression levels and function during latency III
EBV infection utilized EBV-infected cell lines and in vitro EBV-
transformed B cells (LCLs) (7, 10, 11, 37). Technical challenges in
extracting tumors from surrounding noninfected tissue may also
limit our ability to detect BHRF1 miRNA expression in vivo, es-
pecially in the case of smaller tumors. The presence of contami-
nating noninfected tissue may interfere with our ability to detect
miRNA expression in tumor tissue. Nevertheless, despite these
potential challenges, we were able to detect expression of one or
more BHRF miRNAs in the majority of tumors analyzed from
mice infected with WT/REV EBV. Collectively, our results reveal
that the absence of BHRF1 miRNA expression does not impede
the generation of latency III EBV-associated malignancies in vivo.
In conclusion, although we did not directly recapitulate previ-
ously published in vitro results demonstrating that 123 virus
reduced transformation, we did observe a delay in the ability of
123 virus to cause systemic infection. The results of our in vivo
analyses suggest that the mechanism for this delay is most likely
due to decreased growth of infected cells. In addition, they also
indicate that BHRF1 miRNAs are not required for the formation
of latency III EBV-associated malignancies in vivo and that other
viral components are able to compensate for the loss of BHRF1
miRNA activity during tumorigenesis.
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